Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Why demand for CRISPR gene editing is increasingon June 17, 2021 at 3:38 pm
CNBC's Meg Tirrell discusses CRISPR gene editing with one of its inventors, Jennifer Doudna, UC Berkeley biochemist.
- Gene-editing startup incubated at Google goes public in $267M IPOon June 17, 2021 at 10:47 am
Verve Therapeutics, a cholesterol-targeting, gene-editing startup and the first biotech to be incubated by the venture capital arm of Google, has hit the public market in a $267 million IPO — two and ...
- Gene editing biotech Verve to raise $267M in large IPOon June 17, 2021 at 8:42 am
Capitalizing on investor interest in gene editing, the high-profile startup has secured one of the richest biotech initial public offerings priced this year.
- Gene Editing Market Sales and Revenue by Companies, Regions, Type and Application till 2027 | ARCon June 16, 2021 at 9:35 pm
The global gene editing market is expected to reach the market value of around US$ 9.2 Bn by 2026, growing at a CAGR of 15.3% over the forecast period 2019 to 2026. The global Gene Editing Market ...
- Gene editing - A tool to tackle climate changeon June 16, 2021 at 8:04 am
There are about 688 million people undernourished in the world of which 351 million - more than half -- live in the Asia- Pacific region ...
- Gene Editing- Tool to tackle climate change, achieve food security in Asia Pacificon June 16, 2021 at 7:01 am
There are about 688 million people undernourished in the world, of which 351 million - more than half -- live in the Asia- Pacific region.
- Gene Editing Stocks: Should You Add This Cutting-Edge Sector To Your Portfolio?on June 15, 2021 at 11:10 pm
O ur indicative theme of Gene Editing stocks is down by about 12% year-to-date, compared to the S&P 500 which is up by over 13% over the same period. The decline comes as investors move money from ...
- Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?on June 15, 2021 at 6:32 am
Pioneering biotech bluebird bio (NASDAQ:BLUE) has resumed clinical trials for its blood disorder gene therapies after getting clearance from the U.S. Food and Drug Administration (FDA). The stock is ...
- CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorderon June 15, 2021 at 4:31 am
A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines.
- CRISPR on the Cutting Edge of Gene Editing Technologyon June 15, 2021 at 1:37 am
Gene editing plays are among the hottest in the biotech world today. The company’s market capitalization of nearly $10 billion speaks to the degree of confidence investors have in CRISPR’s ability to ...
via Bing News